TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06786650
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
Study: NCT06356129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06356129
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06356129
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06143696
Drug: Qingxin Zishen decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 1 dose daily, twice a day
Study: NCT05610735
Drug: Withaferin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha in the form of tablets will be administered orally on daily basis.
Study: NCT05610735
Drug: Ashwagandha
Normalized name: Ashwagandha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally on daily basis twice a day
Study: NCT05610735
Drug: Combination of ASWD and DOXIL
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
Study: NCT06750094
Drug: Leucovorin calcium/Levoleucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study: NCT05844501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo orally twice daily for 28 days
Study: NCT06503146
Drug: [18F]FAPI-74
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
Study: NCT06503146
Drug: [18F]FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
Study: NCT06516952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06120140
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline tablet will be administered orally.
Study: NCT06120140
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline capsule will be administered orally.
Study: NCT06120140
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin lotion will be used as topical application on the scalp.
Study: NCT04858334
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06435429
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT06741969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC.
Study: NCT06741969
Drug: Standard of care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-defined topical and systemic standard of care background treatments.
Study: NCT06578247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo at 60 mg/day orally once daily
Study: NCT06578247
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Study: NCT05784688
Drug: TU2218 + KEYTRUDA® (Pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered
Study: NCT06282159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
Study: NCT06139328
Drug: Placebo matching BI 765845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 765845
Study: NCT04803201
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04803201
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04821271
Drug: TS-161 (50 - 100 mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 and 2 Experimental Intervention
Study: NCT05907746
Drug: Post-Transplant Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg IV daily on days +3 and +4
Study: NCT05907746
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
Study: NCT06214858
Drug: SHEN211 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
Study: NCT05354063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM on day 0 and day 21.
Study: NCT05828303
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT05550714
Drug: general anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
Study: NCT05550714
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
Study: NCT06530524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of normal saline into the at-risk major salivary glands
Study: NCT05157685
Drug: Azithromycin Oral Tablet
Normalized name: azithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
Study: NCT05157685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
Study: NCT05999708
Drug: GSK4381406
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4381406 will be administered.
Study: NCT05999708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05999708
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin will be administered.
Study: NCT05751668
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05321082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05121051
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06621576
Drug: HM2002 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
Study: NCT04708470
Drug: PDS01ADC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
Study: NCT05115513
Drug: Medium THC
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana flower with medium THC
Study: NCT05115513
Drug: Placebo THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana flower with no THC
Study: NCT06179160
Drug: INCB161734
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB161734 will be administered at protocol defined dose.
Study: NCT06179160
Drug: GEMNabP
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMNabP will be administered at protocol defined dose.
Study: NCT06179160
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX will be administered at protocol defined dose.
Study: NCT06548360
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT04759586
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04759586
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04759586
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05653219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion for intravenous use.
Study: NCT06757010
Drug: NE3107
Approvals — FDA: no, EMA: no, PMDA: no
Description: NE3107 20 mg BID
Study: NCT06757010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT06690281
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
Study: NCT06586112
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESK-001
Study: NCT06586112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06500884
Drug: Prophylaxis B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis B will be administered orally.
Study: NCT06500884
Drug: Prophylaxis C
Normalized name: HERBAL STONE PROPHYLAXIS CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis C will be administered orally.
Study: NCT06515002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06425159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily
Study: NCT06564142
Drug: Placebo (matched to Povetacicept)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Povetacicept subcutaneous injection administration.
Study: NCT06667700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Study: NCT06325293
Drug: Azithromycin Pfizer®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
Study: NCT06325293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control comparator arm: 5 days of placebo
Study: NCT05521438
Drug: QRX003-2% Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
Study: NCT05521438
Drug: QRX003-4% Lotion QAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Study: NCT05521438
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Lotion
Study: NCT05521438
Drug: QRX003-4% Lotion BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Study: NCT05350969
Drug: CDR132L
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Study: NCT05350969
Drug: Placebo to CDR132L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to CDR132L
Study: NCT05672459
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT04301076
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04301076
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01471925
Drug: Nexium®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days.
Study: NCT06318442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT04932005
Drug: DZD2269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
Study: NCT04932005
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
Study: NCT05182073
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning Agent
Study: NCT05900401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
Study: NCT04859439
Drug: DBPR108 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DBPR108, tablet, oral
Study: NCT05915728
Drug: Gadoquatrane (BAY1747846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT06456099
Drug: Ultrasound-guided corticosteroid injection
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
Study: NCT06039592
Drug: Spironolactone Tablets
Normalized name: Spironolactone Tablets
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-4mg/kg, bid
Study: NCT04529265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal volume of normal saline after induction of anesthesia and at the end of surgery
Study: NCT05942352
Drug: Placebo by intravenously administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 250ml saline per day for 15 days
Study: NCT05942352
Drug: Placebo by mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg placebo tablet by mouth would be maintained for 1 year
Study: NCT05511558
Drug: [14C]-Fosgonimeton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon-14 Radiolabeled Fosgonimeton
Study: NCT05110599
Drug: Bryophyllum 50% chewable tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
Study: NCT05825560
Drug: OFA multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal opioid free analgesia
Study: NCT05825560
Drug: Standard multimodal analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard remifentanil analgesia
Study: NCT05244811
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of progestin in treatment of ovarian cystn
Study: NCT02154347
Drug: KAD-1229
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02154347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05089981
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous use of N acetyl cysteine in prescribed doses
Study: NCT05089981
Drug: Placebo of N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
Study: NCT05459220
Drug: SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 Injection（Low Dose）
Study: NCT05459220
Drug: SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 Injection（High Dose）
Study: NCT05459220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for SHR0410 Injection.
Study: NCT06414512
Drug: AMBITION trial control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
Study: NCT05647551
Drug: BOTOX®/VISTABEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial Injection
Study: NCT05982080
Drug: FP002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
Study: NCT06539507
Drug: BCX17725
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX17725 for injection
Study: NCT06539507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for injection
Study: NCT04930237
Drug: Relistor Injectable Product
Normalized name: Relistor Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
Study: NCT05466539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
Study: NCT04732429
Drug: HST5040
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid solution
Study: NCT04732429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid solution
Study: NCT04925674
Drug: HEC53856
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.
Study: NCT05583214
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be given IV stat to the group after induction of spinal anesthesia
Study: NCT06450574
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Study: NCT04678908
Drug: HB0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
Study: NCT04692376
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
Study: NCT05550597
Drug: Fentanyl HCl
Normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia